Author

Remy Bell

Harvard UniversityORCID 0000-0002-4737-6553Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Assay:imaging· 1 Approach:statistical model· 1

Frequent Co-Authors

Avanish MishraiD· 2 shared Mehmet ToneriD· 2 shared Quinn E. CunneelyiD· 2 shared Victor R. PutaturoiD· 2 shared Aditya BardiaiD· 1 shared Adriana Payan-MedinaiD· 1 shared Akansha Deshpande· 1 shared Charles S. Dai· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Avanish MishraORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioengineeringbioRxivPreprintJul 31, 2026

Microfluidic T-Chip enables one-step clinical-scale T-cell purification from blood products for CAR T-cell manufacturing

Maheen Rana, Sophia E. Nigrovic, Adriana Payan-Medina…·Avanish Mishra

The paper introduces a microfluidic T-Chip for one-step clinical-scale T-cell purification from blood products, achieving high purity, viability, and recovery of CD3+ T cells for CAR T-cell manufacturing.

DOI 10.64898/2026.07.30.741793

humanflow cytometry

Cancer BiologyProceedings of the National Academy of SciencesPeer-reviewedJun 17, 2026

✦ In-depth digest

Dynamic Monitoring of Antibody Drug Conjugates Targeting TROP2 or HER2 in Breast Cancer using Circulating Tumor Cells

Avanish Mishra, Rachel O. Abelman, Quinn E. Cunneely…·Shyamala Maheswaran

In metastatic breast cancer on TROP2- or HER2-targeting antibody-drug conjugates, early CTC disappearance or steep decline tracked response, while CTC epitope levels neither predicted benefit nor vanished at resistance.

9 citationstop 1%

humanimaging